Litigator of the Week
There's no question that the smartphone patent wars are a bruising business. And in the headline battle — Apple Inc.'s fight with Samsung Electronics Co. — Samsung is looking especially black and blue this month.
For Martens and his bosses in Washington, the stakes in the trial of Fabrice Tourre were huge.
Coffin and his team at Steptoe won a ruling in Washington that could dramatically reduce the fees nationwide banks can impose on merchants that accept debit cards, saving restaurants and retailers billions of dollars every year.
A dozen years on, American Airlines still faces negligence claims related to Flight 11, the hijacked plane that destroyed the World Trade Center's North Tower on 9/11. But the airline took a giant step forward when Podesta and Monaghan won a verdict wiping out billions of dollars in potential liability to WTC real estate developer Larry Silverstein.
There's a reason Lumish has been a hot ticket lately on the lateral market: In his first trial since joining Latham in May, the IP litigator knocked out patent claims against TransPerfect Translation International that had threatened to derail the company's business, leaving his adversaries saddled with a $1 million damages award instead.
It wasn't quick and it wasn't easy, but Brooks finally wiped out a $149 million patent case that Baxter International brought against her client, Fresenius. In the process, she may have helped to reinforce a common tactic in the patent defense playbook.
It took a federal jury in Marshall, Tex., just 75 minutes to return a verdict that the Gap Inc. doesn't infringe on patents related to gift cards. For Alan Fisch it was his fourth defense verdict in the Eastern District of Texas.
Kaplan's tireless advocacy on behalf of the gay rights cause, as well as the remarkable support she's lent to client Edith Windsor, were rewarded in this week's landmark Supreme Court ruling.
Until this week, the government's crusade against pharmaceutical pay-for-delay deals was on decidedly shaky ground. Now, thanks to Stewart and his team, drug companies may need to reevaluate part of their business model.